MedPath

Effect of Milk on the Vaccination Response

Not Applicable
Completed
Conditions
Infection
Interventions
Biological: cholera vaccination
Other: pasteurized milk
Other: UHT milk
Other: raw milk
Registration Number
NCT02924246
Lead Sponsor
NIZO Food Research
Brief Summary

Rationale: Oral vaccination is known to induce a systemic immune response as well as an immune response in mucosal tissues, and can therefore serve as a model to study systemic and mucosal immunity. In this study, the oral cholera vaccine Dukoral® was chosen as model vaccine. The kinetics of the immune response and the interaction with a raw milk matrix have been evaluated in a previous, pilot study (NL49042.081.14). Based on the outcomes of this pilot, in this study oral cholera vaccination will be applied to study the support of immunity by raw milk, compared to heat-treated milk. The study design has been optimised based on previous results: study duration is extended and sample size is based on relevant change and known variation in the primary outcome parameters.

Infections are an important worldwide cause of death, both in elderly and young children. Therefore, support of immunity could help to reduce the incidence of infections. To screen the potential of specific foods or food ingredients to support immunity, oral vaccination can serve as a model. In a previous study, this model was developed using oral cholera vaccination in human adult volunteers. In that study, raw milk was shown to support the immune response to vaccination. In this follow-up study, the effect of raw milk will be compared with pasteurized and ultra-heat treated (UHT) milk.

Objective: To investigate whether pasteurized milk and/or UHT milk are able to enhance the immune response as induced by oral cholera vaccination, in comparison to raw milk and to regular vaccination.

Study design: The study is designed as a single-blind randomized controlled trial of 6 weeks.

Study population: Healthy subjects of 18-50 years of age.

Interventions: 1) Raw milk, obtained from farms that comply to the high quality requirements for production of raw milk, and that has been screened according to the safety criteria for raw milk; 2) commercially available full-fat UHT milk; 3) commercially available full-fat pasteurized milk.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
108
Inclusion Criteria
  • Age 18-50 yr
  • Signed informed consent
  • Availability of internet connection
  • Male or female
  • Willing to stop blood donation at the blood bank during the study period
Exclusion Criteria
  • Currently participating in another clinical trial
  • Previous Cholera, Salmonella, or E. coli vaccination
  • Tonsillectomy
  • Acute gastroenteritis in the past 2 months
  • Use of antibiotics in the past 2 months
  • Hypersensitivity to the vaccine, to formaldehyde or to any of the excipients (sodium salts)
  • Pregnancy or lactating
  • Not willing to drink raw milk
  • Allergic to milk or lactose-intolerant
  • Disease of GI tract, liver, gall bladder, kidneys, thyroid gland
  • Immune-compromised
  • Use of immunosuppressive drugs
  • Drug abuse, and not willing/able to stop this during the study
  • Excessive alcohol usage (men: >4 consumptions/day or >20 consumptions/week; women: >3 consumptions/day or >15 consumptions/week)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
UHT milkcholera vaccinationCholera vaccination - UHT milk
Pasteurized milkpasteurized milkCholera vaccination - pasteurized milk
UHT milkUHT milkCholera vaccination - UHT milk
Control groupcholera vaccinationRegular cholera vaccination
Raw milkcholera vaccinationCholera vaccination - raw milk
Raw milkraw milkCholera vaccination - raw milk
Pasteurized milkcholera vaccinationCholera vaccination - pasteurized milk
Primary Outcome Measures
NameTimeMethod
Change in cholera toxin-specific IgA and IgG antibody level in serum as a marker of the vaccination responsebaseline and day 14, 28, 42
Secondary Outcome Measures
NameTimeMethod
Change in the cholera toxin-specific IgA and IgG antibody level in nasal wash as a marker of the vaccination responsebaseline and day 14, 28, 42
Change in the cholera toxin-specific IgA and IgG antibody level in saliva as a marker of the vaccination responsebaseline and day 14, 28, 42
Change in the cholera toxin-specific IgA antibody level in feces as a marker of the vaccination responsebaseline and day 14, 28, 42

Trial Locations

Locations (1)

NIZO food research

🇳🇱

Ede, Netherlands

© Copyright 2025. All Rights Reserved by MedPath